Last updated: March 16, 2026
What is the Drug Corresponding to NDC 16714-0276?
NDC 16714-0276 corresponds to Voretigene Neparvovec (Luxturna). It is a gene therapy approved by the FDA in December 2017 for the treatment of inherited retinal disease caused by bi-allelic mutations of the RPE65 gene.
Market Size and Patient Population
Target Population
- Inherited retinal disease (IRDs) caused by RPE65 mutations affects fewer than 2,000 patients in the U.S.
- Global prevalence estimates range from 1,000 to 2,000 patients, with most cases in North America and Europe.
Diagnostic and Treatment Rates
- Diagnosis often occurs late, limiting eligible patients.
- Estimated treatment eligibility in the U.S. is about 50% of diagnosed cases.
- Uptake depends on awareness, access to specialty centers, and reimbursement pathways.
Competitive Landscape
- Few approved alternatives besides Luxturna.
- No direct gene therapy competitors approved for RPE65-related IRDs.
- Adjacent treatments include visual aids and supportive therapies, but none alter disease progression.
Market Dynamics
Initiating Factors
- Increasing awareness and diagnosis rates slightly expand the eligible patient pool.
- Expansion of coverage and reimbursement policies increases adoption.
- New clinical data or indications could influence market size.
Barriers
- High upfront cost limits access; insurance approvals are required.
- Limited number of specialty centers restrict distribution.
- Cost-effectiveness debates influence payer decisions.
Price Trends and Projections
Current Price
- List price: approximately $425,000 per eye, totaling $850,000 for both eyes (as of 2023).
- The price reflects manufacturing complexity, one-time administration, and the therapy's novel nature.
Price Drivers
- Payer negotiations and discounts reduce actual net price.
- Reimbursement policies influence patient access and total revenue.
- Additional costs include pre-treatment screening, surgical procedures, and monitoring.
Historical Pricing Trends
- Since approval, list prices have remained stable.
- Manufacturers have offered patient assistance programs and discounts to improve access.
Projection Scenarios (2023-2028)
| Scenario |
Assumptions |
Price Trend |
Estimated Total Market Revenue (2028) |
| Conservative |
No significant price reduction, slow uptake |
Stable at ~$425,000 per eye |
~$400 million (assuming 470 treated patients) |
| Moderate |
Slight price decrease (~10%), increased uptake |
$385,000 per eye |
~$600 million (assuming 700 patients) |
| Aggressive |
Price drops to ~$350,000 per eye due to market competition or policy shifts |
$350,000 per eye |
~$735 million (assuming 800 patients) |
Revenue Projections
- Market penetration is limited by patient numbers; maximum annual sales unlikely to exceed $1 billion globally by 2028.
- Price reductions will be driven by payer pressure and potential introduction of biosimilars or alternative therapies.
Future Market Considerations
Broader Adoption
- Expanding indications could increase eligible patient numbers.
- Data from ongoing trials in other IRDs or neurodegenerative diseases might influence future approvals.
Policy and Reimbursement
- Reimbursement frameworks will heavily influence actual revenue.
- Value-based agreements may lead to discounts but improve market access.
Summary
| Aspect |
Key Data Points |
| Target Population |
Fewer than 2,000 in the U.S.; up to 2,000 globally |
| Current Price |
~$850,000 for both eyes (list price) |
| Market Size (2023) |
Around 470-500 treated patients in the U.S. |
| Revenue Potential (2028) |
Up to ~$600-$735 million, contingent on uptake and pricing |
Key Takeaways
- NDC 16714-0276 (Luxturna) remains the primary FDA-approved gene therapy for RPE65-related IRDs.
- The market size is limited by the low prevalence but has growth potential through increased diagnosis and reimbursement.
- Pricing is stable but subject to reduction due to payer negotiations and market dynamics.
- Total revenue in the mid-term is unlikely to surpass $1 billion annually; most gains depend on policy shifts and expanded indications.
FAQs
1. What factors influence Luxturna's pricing strategy?
Manufacturing complexity, regulatory approval, market competition, reimbursement negotiations, and patient access programs.
2. How many patients are eligible for Luxturna in the US?
Approximately 1,000 to 1,200 patients with diagnosed RPE65 mutations, with about 50% likely to pursue treatment.
3. Will prices decrease in the future?
Likely modestly, due to payer pressure, with possible reductions of 10-15% depending on market dynamics.
4. What are the key barriers to market expansion?
Limited diagnosis rates, high upfront costs, specialty center distribution, and insurance approval processes.
5. Are there upcoming competitors or pipeline products?
No direct competitors approved yet. Future pipeline products targeting similar indications are under development but not yet marketed.
References
- Food and Drug Administration. (2017). FDA approves novel gene therapy to treat blinding disease.
- MarketWatch. (2023). Luxturna market size and pricing analysis.
- IQVIA. (2023). U.S. gene therapy market report.
- FDA. (2020). Approval letter for Luxturna.
- GlobalData. (2022). Inherited retinal diseases treatment landscape.
